Close
ACHEMA MIDDLE EAST 2026
5th LNP Formulation & Process Development Summit

Clinical Trials

Allergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for Double-Chin

Clinical Trials
Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc., a company...

KYBELLA® Injection Wins Allure Magazine “Best of Beauty” Award

Clinical Trials
Allergan, plc (NYSE: AGN) is pleased to announce that KYBELLA® (deoxycholic acid) injection, the first and only FDA-approved injectable treatment for improving the appearance...

ABBVIE ANNOUNCES PLANS TO PROCEED TO PHASE 3 EVALUATION OF ELAGOLIX IN PATIENTS WITH UTERINE FIBROIDS

Clinical Trials
AbbVie (NYSE: ABBV), in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the completion of a Phase 2b clinical trial evaluating the safety...

Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015

Americas
Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections known as MSD outside the United...

Long-Term, 7-Year Study of Nulojix® Regimen Demonstrates Statistically Significant Relative Risk Reduction of Death or Graft Loss over Cyclosporine Regimen in Kidney Transplant

Clinical Trials
Bristol-Myers Squibb Company announced results from a 7-year, long-term follow-up from a prospective, randomized Phase III trial (BENEFIT) in kidney transplant patients, which demonstrated...

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients...

Clinical Trials
Today announced that primary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily...

Alizé Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome

Clinical Trials
Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

Whitepapers 0
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

Whitepapers 0
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Whitepapers 0
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...

About us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and
comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector. . . Read More

Resources

Advertise

Subscribe

Copyright © Value Media Group 2026. All rights reserved.